Article Per Year (5 Year)
p-Index From 2019 - 2024
0.817
P-Index
This Author published in this journals
All Journal JURNAL ILMU KEFARMASIAN INDONESIA Pharmaceutical And Biomedical Sciences Journal (PBSJ)
Manninda, Reise
Fakultas Farmasi Universitas Pancasila, Jakarta 12630, Indonesia
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Analisis Dampak Program Pengelolaan Penyakit Kronis (Prolanis) Dalam Meningkatkan Outcome Klinis Pasien Diabetes Melitus Tipe 2 Di Puskesmas Jakarta, Indonesia Reise Manninda; Yusi Anggriani; Astrid Kartika Sari
JURNAL ILMU KEFARMASIAN INDONESIA Vol 19 No 2 (2021): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v19i2.1107

Abstract

Prolanis is a Chronic Disease Management Program under the Indonesian National Health Insurance for promoting and preventing chronic disease. Main activities of Prolanis program are disease control and counseling, scheduled education, scheduled exercise, participant’s remainder, and home visit. The aim of this study was to evaluate the impact of prolanis on the clinical outcome in type 2 Diabetes Mellitus (DM) patients. An observational retrospective study was evaluated for 12 months. Data was collected from medical record. 426 patients from five primary health care center in Jakarta was selected by simple random sampling and divided into prolanis and non-prolanis groups. The indicators were the difference of clinical outcome between prolanis and non-prolanis patients was analyzed using Mann-Whitney test; the correlation of adherence with clinical outcome was analyzed using Chi-Square test.The results showed that prolanis patients had a significant improvement in Fasting Blood Glucose (FBG) compared with non-prolanis patients (P<0.05). The adherence of prolanis patients showed a significant improvement on FBG (124 patients-58.2%). Patients with nonadherence had lower improvement on FBG, the improvement was observed only at 16 patients (7.5%) and 60 patients (28.17%) was poor FBG. Prolanis is an effective program to improve the clinical outcome of DM patients.
Analisis Efektivitas Biaya Pengobatan Kombinasi Zidovudin, Lamivudin, Nevirapin dan Kombinasi Tenofovir, Lamivudin, Efavirenz Pada Pasien HIV/AIDS di RSUD Kota Bekasi Yusi Anggriani; Fredrick D. Purba; Reise Manninda; Tarsinah Tarsinah
JURNAL ILMU KEFARMASIAN INDONESIA Vol 18 No 2 (2020): JIFI
Publisher : Fakultas Farmasi Universitas Pancasila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35814/jifi.v18i2.905

Abstract

HIV/AIDS has become a global issue in many countries. The implementation of ARV / HAARTprograms is always changing, due to clinical reasons, population factors, and aff ordability. Pharmacoeconomic studies can be one of the considerations in the policy process for procurement and selection of therapy regimens. The aims of this study were to determine the eff ectiveness of treatment based on CD4 increase and cost eff ectiveness analysis of HAART A and HAART B treatment regimens. This study used a cross sectional observation method. Retrospective data collection and non-experimental observation where conducted followes by a quantitative descriptive analysis according to the patient's perspective to obtain costeffectiveness data. Data were statistically analyzed to obtain the cost-eff ectiveness of treatment. The results showed that the cost-eff ectiveness analysis (CEA) of two regimens found that HAART A was more dominant than HAART B with a signifi cant diff erence p<0.05. While ACER regimen HAART A (16,227) was greater than the value ACER therapy B (28,330.7).
Faktor Resiko Penyebab Multidrug Resistant Tuberkulosis: Sistematik Review Mita Restinia; Sondang Khairani; Reise Manninda
Pharmaceutical and Biomedical Sciences Journal (PBSJ) Vol 3, No 1 (2021)
Publisher : UIN Syarif Hidayatullah Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (379.775 KB) | DOI: 10.15408/pbsj.v3i1.20049

Abstract

Indonesia merupakan negara kedua dengan jumlah kasus tuberkulosis terbanyak di dunia. Pengobatan Tuberkulosis di Indonesia semakin sulit dengan munculnya Multidrug Resistant Tuberculosis (MDR-TB). Penelitian dilakukan untuk mengetahui faktor resiko yang menyebabkan terjadinya MDRT-TB di Indonesia. Sistematik review dilakukan terhadap artikel dengan studi case control. MDR-TB sebagai kelompok kasus dan Non MDR-TB sebagai kelompok kontrol. Artikel yang dipilih adalah artikel yang dipublikasikan pada tahun 2015-2020. Artikel dicari  melalui database google schoolar dan dianalisa menggunakan Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). Terdapat 9 original artikel yang memenuhi kriteria inklusi untuk dianalisa. Faktor resiko terjadinya MDR-TB dibagi menjadi tiga kelompok yaitu karakteristik responden, Riwayat TB dan pengobatan, dan komorbiditas. Karakteristik responden yang signifikan mempengaruhi terjadinya MDR TB adalah dukungan keluarga, pengetahuan, usia, dan akses ke fasilitas kesehatan. Tidak patuh minum obat, adanya riwayat pengobatan TB, tidak aktif pengawas minum obat, efek samping obat dan adanya komorbiditas juga merupakan faktor resiko terjadinya MDR-TB.  Hasil yang diperoleh dapat disimpulkan bahwa identifikasi faktor resiko terjadinya MDR TB perlu dilakukan dengan baik. Selain itu, Pasien TB yang memiliki faktor resiko perlu diberikan edukasi yang lebih komprehensif dan pengawasan minum obat secara lebih ketat  untuk mencegah terjadinya MDR TB.
Co-Authors Ade Rosanti Anggriani, Yusi Astrid Kartika Sari Evy Yunihastuti Fredrick D. Purba Mita Restinia Rifka Annisa Sondang Khairani Tarsinah Tarsinah Yulia Trisna Yusi Anggriani